The weekly litigation news digest is live. Subscribe now

IP Verse

Polymorphic And Pseudopolymorphic Forms Of Pharmaceutical Compound Nxl104 - EP3269717

The patent EP3269717 was granted to Pfizer on Aug 9, 2023. The application was filed on Oct 8, 2010 under application number EP17182561A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3269717

PFIZER
Application Number
EP17182561A
Filing Date
Oct 8, 2010
Status
Patent Maintained As Amended
May 12, 2023
Publication Date
Aug 9, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBNov 26, 2019LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONFR2921060
DESCRIPTIONUS6417175
DESCRIPTIONUS6906055
DESCRIPTIONUS7419973
DESCRIPTIONWO0210172
DESCRIPTIONWO03063864
OPPOSITIONEP2135959
OPPOSITIONUS7112592
SEARCHWO0210172

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents